logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Ipsen Biopharmaceuticals, Inc. drugs

    FiltersReset Filters
    7 results

    • bylvay

      (odevixibat)
      Ipsen Biopharmaceuticals, Inc.
      Usage: BYLVAY is indicated for treating pruritus in patients 3 months and older with Progressive Familial Intrahepatic Cholestasis (PFIC) and cholestatic pruritus in patients 12 months and older with Alagille Syndrome (ALGS). Note: it may not be effective for all PFIC type 2 patients.

    • dysport - botulinum toxin type a injection, powder, lyophilized, for solution

      (Botulinum Toxin Type A)
      Ipsen Biopharmaceuticals, Inc.

    • increlex

      (mecasermin)
      Ipsen Biopharmaceuticals, Inc.
      Usage: INCRELEX is indicated for treating growth failure in pediatric patients aged 2 and older with severe primary IGF-1 deficiency or growth hormone gene deletion and neutralizing antibodies to GH. It is not a substitute for growth hormone and is not intended for secondary IGF-1 deficiencies.

    • iqirvo

      (elafibranor)
      Ipsen Biopharmaceuticals, Inc.
      Usage: IQIRVO is indicated for treating primary biliary cholangitis (PBC) in adults, used with ursodeoxycholic acid (UDCA) for those with inadequate response or as monotherapy for those intolerant to UDCA. Its approval is based on alkaline phosphatase reduction, not demonstrated improvement in survival or liver events.

    • onivyde

      (IRINOTECAN HYDROCHLORIDE)
      Ipsen Biopharmaceuticals, Inc.
      Usage: ONIVYDE is indicated for use in combination with other medications for treating metastatic pancreatic adenocarcinoma in adults, both as a first-line treatment and after progression on gemcitabine-based therapy. It is not approved as a standalone treatment for this condition.

    • sohonos

      (palovarotene)
      Ipsen Biopharmaceuticals, Inc.
      Usage: SOHONOS is indicated for reducing the volume of new heterotopic ossification in adults and pediatric patients with fibrodysplasia ossificans progressiva (FOP), specifically in females aged 8 years and older and males aged 10 years and older.

    • somatuline depot

      (lanreotide acetate)
      Ipsen Biopharmaceuticals, Inc.
      Usage: SOMATULINE DEPOT is indicated for long-term treatment of acromegaly, unresectable gastroenteropancreatic neuroendocrine tumors (GEP-NETs), and carcinoid syndrome in adults. It aims to normalize growth hormone levels, improve progression-free survival in GEP-NETs, and reduce the need for short-acting somatostatin analog rescue therapy in carcinoid syndrome.